Previous 10 | Next 10 |
home / stock / frx:cc / frx:cc news
~ Achieved First Quarter 2024 Total Net Revenues of $25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction ~ ~ Executed Exclusive Licensing Agreement with Norgine to Commercialize PEDMARQSI™ in Europe, Australia, ...
Gold Springs Resource Corp. (GRC:CA) is expected to report for Q1 2024 Primo Water Corporation (PRMW:CA) is expected to report $0.18 for Q1 2024 Greenlane Renewables Inc. (GRN:CA) is expected to report $-0.01 for Q1 2024 Kelso Technologies Inc. (KLS:CA) is expected to report for Q1 20...
RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2024 financial results before the opening of the U.S. financial...
Bridgemarq Real Estate Services Inc. Restricted Voting Shares (BRE:CA) is expected to report for quarter end 2023-12-31 Avivagen Inc. (VIV:CA) is expected to report for quarter end 2024-01-31 Andean Precious Metals Corp. (APM:CA) is expected to report $0 for Q4 2023 Aimia Inc. (AIM:CA...
~ Achieved PEDMARK ® Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~ ~ Entered Into Exclusive Licensing Agreement to Commercialize PEDMARQSI™ in Europe, Australia and New Zealand for Appro...
RESEARCH TRIANGLE PARK, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2023 financial results before the opening of t...
Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI ® , the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic soli...
~ Fourth Quarter 2023 Net Revenues of Approximately $9.2 to $9.7 Million ~ ~ Company Expects to Report 2023 Fourth Quarter and Audited Full-Year Results on or about March 26, 2024 ~ RESEARCH TRIANGLE PARK, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NA...
RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a public reminder to healthcare providers that PED...
~ Supports Strategic Discussions and Global Launch Activities ~ ~ Extends Access to Additional Undrawn Capital As Needed During Global PEDMARK ® Rollout ~ ~ Facilitates Market Expansion into the Adolescent and Young Adult (AYA) Patient Population ~ RESEARCH TRIANG...
News, Short Squeeze, Breakout and More Instantly...
Fennec Pharmaceuticals Inc. Company Name:
FRX:CC Stock Symbol:
TSXC Market:
Fennec Pharmaceuticals Inc. Website:
A look at the top 10 most actives in Canada Fission Uranium Corp. (FCU) rose 5.9% to $1.25 on volume of 21,445,305 shares iShares S&P/TSX 60 Index ETF (XIU) rose 1.4% to $33.6 on volume of 18,474,835 shares TC Energy Corporation (TRP) rose 1.1% to $52.16 on volume of 14,728,718 shares...
RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that Adrian Haigh has departed from his position as Fennec’s Chief Operating Officer as of June 30, 202...
A look at the top 10 most actives in Canada TC Energy Corporation (TRP) fell 1.3% to $52.81 on volume of 17,383,455 shares Canadian Natural Resources Limited (CNQ) fell 0.0% to $48.35 on volume of 13,616,778 shares Enbridge Inc. (ENB) rose 1.4% to $48.43 on volume of 12,909,121 shares C...